

RETRACTION NOTE OPEN



Retraction Note to: Inhibition of TGF- β repairs spinal cord injury by attenuating EphrinB2 expressing through inducing miR-484 from fibroblast

Dayu Pan, Fuhan Yang, Shibo Zhu, Yongjin Li, Guangzhi Ning and Shiqing Feng

© The Author(s) 2022

Cell Death Discovery (2022)8:369; <https://doi.org/10.1038/s41420-022-01159-2>

Retraction to: *Cell Death Discovery* <https://doi.org/10.1038/s41420-021-00705-8>, published online 28 Oct 2021

The Editors-in-Chief have retracted this article at the authors' request. After publication, the authors became aware of significant issues with the data presented here. Specifically:

- The authors have found that the described effect of 1D11 TGF- β neutralizing antibody on fibrotic scar formation after spinal cord injury appears to be time-dependent and further experiments do not support the results and conclusions presented in this paper.
- The authors have used the staining of EphrinB2, a ligand, to measure the expression of Eph Receptor B2 (EphB2, a receptor). This is incorrect and readers should disregard the data and conclusions based on this part of the study.
- As per article title, the project investigated miR-484, but it was referred to as miR-488 throughout the text by mistake.

The authors have lost confidence in the results and conclusions presented in this article.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2022